Skip to main content

Table 1 Baseline demographic and clinical characteristics of the study population (N = 47)

From: The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China

Characteristics

 

Mean age at diagnosis (SD), y

54.38 (11.57)

Sex (%)

 Male

20 (43)

 Female

27 (57)

Performance status (%)

 <2

36 (77)

  ≥ 2

11 (23)

Smoking history (%)

 Current and former

15 (32)

 Never

32 (68)

Charlson Comorbidity Index (%)

 0

12 (25)

 1–2

25 (53)

  ≥ 3

10 (21)

Histology (%)

 Adenocarcinoma

46 (98)

 Adenosquamous carcinoma

1 (2)

Stage at diagnosis

 IIIB

7 (15)

 IV

40 (85)

Number of metastatic sites (%)

 1–2

33 (70)

  ≥ 3

14 (30)

Metastatic site Brain (%)

 No

41 (87)

 Yes

6 (15)

Liver (%)

 No

45 (96)

 Yes

2 (4)

Lung (%)

 No

35 (74)

 Yes

12 (26)

Adrenal (%)

 No

43 (91)

 Yes

4 (9)

Soft tissue (%)

 No

45 (96)

 Yes

2 (4)

Bone (%)

 No

34 (72)

 Yes

13 (28)

Pleural (%)

 No

25 (53)

 Yes

22 (47)

Lymph node (%)

 No

13 (28)

 Yes

34 (72)

All lines therapy (%)

 Chemotherapy

19 (26)

 ROS1TKIs

37 (51)

 Others

16 (22)

First-line therapy (%)

 First-line ROS1 TKIs

24 (51)

 Chemotherapy

13 (28)

 Others

10 (21)

Ros-1 TKIs (%)

 Ros-1 TKIs at first-line therapy

24 (65)

 Ros-1 TKIs at any line therapy

13 (35)

Baseline laboratory values (Means, SD)

 Leukocyte count

8.26 (4.04)

 Neutrophil count

5.98 (3.83)

 Hemoglobin

135.67 (16.56)

 Platelet count

281.78 (76.04)

 Carcinoembryonic antigen (CEA)

15.34 (33.44)

 Lactate dehydrogenase (LDH)

238.56 (109.37)

 C-reactive protein (CRP)

13.67 (18.00)

 D-dimer

3.97 (6.41)

  1. Abbreviations: SD Standard deviation, TKIs Tyrosine kinase inhibitors, CEA Carcinoembryonic antigen, LDH Lactate dehydrogenase, CRP C-reactive protein